Pneumococcal vaccine and otitis media

Lancet. 1980 Sep 13;2(8194):547-51. doi: 10.1016/s0140-6736(80)91989-3.

Abstract

After an acute attack of otitis media 827 children aged 3 months to 6 years were assigned randomly to receive either 14-valent pneumococcal polysaccharide vaccine or a control vaccine (Haemophilus influenzae type b capsular polysaccharide). In children older than 6 months serum antibody responses to most of the vaccine polysaccharides were satisfactory. The response to type 6A was poor. Correspondingly, no clinical protection was seen below 6 months of age or against otitis media caused by group 6 pneumococci. Among the children more than 6 months old, the first 6 months after vaccination saw significantly (p < 0.001) fewer attacks caused by the pneumococal types represented in the vaccine (group 6 excepted) in those who received the pneumococcal vaccine than in those who received the control vaccine. Protection against type 19F was statistically significant (p < 0.01). The overall protective efficacy was 58%--somewhat better in children older than 2 years than in those younger. Previous attacks of otitis caused by pneumococci did not influence the protective efficacy of the vaccine.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Bacterial Vaccines / therapeutic use*
  • Child, Preschool
  • Haemophilus Infections / prevention & control
  • Haemophilus influenzae / immunology
  • Humans
  • Otitis Media / immunology
  • Otitis Media / prevention & control*
  • Pneumococcal Infections / prevention & control
  • Polysaccharides, Bacterial / immunology
  • Streptococcus pneumoniae / immunology*
  • Vaccination

Substances

  • Bacterial Vaccines
  • Polysaccharides, Bacterial